Equity Profile

TEVA

Teva Pharmaceutical Industries Limited

Health CarePharmaceuticals$42.6B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical industry, focusing on generic and specialty medications. With a market cap of $43 billion, Teva plays a crucial role in healthcare by providing affordable medicines and addressing various medical needs.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.70

Revenue

Revenue figures reflect the company's sales performance and market demand for its products, impacting overall growth.

$4.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining 11.89% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Teva to continue its positive momentum with an EPS of $0.70 and revenue of $4.2 billion this quarter. The market is keen to see if the company can maintain its growth trajectory.

Bull Case

If Teva beats EPS expectations, it could signal strong operational efficiency and robust demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, if Teva misses expectations or provides weak guidance, it could raise concerns about its market position and future growth, leading to a negative reaction from investors.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.70

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$4.2B

Revenue figures reflect the company's sales performance and market demand for its products, impacting overall growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Teva's EPS exceed the consensus estimate of $0.70?

A beat on EPS could reinforce investor confidence in the company's growth strategy and operational effectiveness.

What is the outlook for revenue growth in the upcoming quarters?

Guidance on revenue growth will be critical for assessing Teva's ability to navigate market challenges and capitalize on opportunities.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Teva's ability to leverage its generic portfolio for growth, especially in emerging markets.

Supporting Evidence

Teva's recent performance shows a consistent ability to beat EPS estimates, indicating strong management execution.

The options market is pricing a smaller move than historical averages, suggesting potential for a larger reaction.

Key Risk

If Teva's revenue growth exceeds $4.4 billion, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on whether Teva can sustain its recent positive earnings surprises and provide solid guidance.

Bull Confirmed If

An EPS of $0.75 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.65 would raise concerns about profitability and market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a potential move of about 5.66%, indicating some uncertainty around the earnings report.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests a potential stock increase of around 3.79%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should Teva miss expectations, history indicates a potential decline of around 3.79%, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into market share changes in key therapeutic areas.
3Comments on cost management strategies and operational efficiencies.
4Guidance on revenue expectations for the next quarter and beyond.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.70

Revenue

Revenue figures reflect the company's sales performance and market demand for its products, impacting overall growth.

$4.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by 8.83%. The stock reacted positively, gaining 11.89% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Teva to continue its positive momentum with an EPS of $0.70 and revenue of $4.2 billion this quarter. The market is keen to see if the company can maintain its growth trajectory.

Bull Case

If Teva beats EPS expectations, it could signal strong operational efficiency and robust demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, if Teva misses expectations or provides weak guidance, it could raise concerns about its market position and future growth, leading to a negative reaction from investors.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.70

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$4.2B

Revenue figures reflect the company's sales performance and market demand for its products, impacting overall growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Teva's EPS exceed the consensus estimate of $0.70?

A beat on EPS could reinforce investor confidence in the company's growth strategy and operational effectiveness.

What is the outlook for revenue growth in the upcoming quarters?

Guidance on revenue growth will be critical for assessing Teva's ability to navigate market challenges and capitalize on opportunities.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Teva's ability to leverage its generic portfolio for growth, especially in emerging markets.

Supporting Evidence

Teva's recent performance shows a consistent ability to beat EPS estimates, indicating strong management execution.

The options market is pricing a smaller move than historical averages, suggesting potential for a larger reaction.

Key Risk

If Teva's revenue growth exceeds $4.4 billion, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on whether Teva can sustain its recent positive earnings surprises and provide solid guidance.

Bull Confirmed If

An EPS of $0.75 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.65 would raise concerns about profitability and market competitiveness.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a potential move of about 5.66%, indicating some uncertainty around the earnings report.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests a potential stock increase of around 3.79%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should Teva miss expectations, history indicates a potential decline of around 3.79%, raising concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into market share changes in key therapeutic areas.
3Comments on cost management strategies and operational efficiencies.
4Guidance on revenue expectations for the next quarter and beyond.